Sulfonylureas and related compounds and use of same

A compound of formula (II) or (III), or a pharmaceutically acceptable salt or solvate thereof:

• wherein:
• W2 and R2 form an indacene group or a substituted or hydrogenated variant thereof;
• and
• (R1)2N— in formula (II) or A in formula (III) is selected from the group consisting of:
• wherein:
• each dashed line may independently be a bond;
• T is O or S;
• A, B, D, E, W, X, Y and Z, when present, are each independently selected from O, C(R3), C(R3)2, N, N(R3) and S;
• each incidence of R3 is independently selected from the group consisting of hydrogen, halide, cyano, C1-C6 alkyl, C1-C6 trifluoroalkyl, C1-C6 alkoxy, C═O, SO2, acyl, amino, hydroxyl, C5-C6 heteroaryl, C5-C6 heterocyclyl and C3-C6 cycloalkyl, each of which may be optionally substituted;
• and
• n is 0, 1, 2 or 3.

A compound of formula (II) or (III), or a pharmaceutically acceptable salt or solvate thereof:

• wherein:
• each R1 is independently selected from a hydrogen atom and pyrazole, imidazole, triazole, tetrazole, pyrrole, morpholine, piperazine, 4-methyl piperazine, and fused bicyclics or tricyclics comprising a benzene ring fused with at least one 5-membered heterocycle, each of which groups may be optionally substituted at a ring atom with a group selected from halo, isopropyl, morpholinyl, piperidinyl, and piperazinyl, each of which groups may themselves be optionally substituted with C1-C6 alkyl;
• A is selected from pyrazole, imidazole, triazole, tetrazole, pyrrole, morpholine, piperazine, 4-methyl piperazine, and fused bicyclics or tricyclics comprising a benzene ring fused with at least one 5-membered heterocycle, each of which groups may be optionally substituted at a ring atom with a group selected from halo, isopropyl, morpholinyl, piperidinyl, and piperazinyl, each of which groups may themselves be optionally substituted with C1-C6 alkyl;
• and
• W2 and R2 form an indacene group or a substituted or hydrogenated variant thereof.

A prodrug of a compound, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is a compound of formula (II) or (III), or a pharmaceutically acceptable salt or solvate thereof:

• wherein:
• R1 is independently selected from the group consisting of hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted;
• and
• A is heteroaryl or heterocyclyl, each of which is optionally substituted and linked to the sulfonyl sulphur through a ring nitrogen;
• and
• W2 and R2 form an indacene group or a substituted or hydrogenated variant thereof.

A prodrug of a compound, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is a compound of formula (II) or (III), or a pharmaceutically acceptable salt or solvate thereof:

• wherein:
• W2 and R2 form an indacene group or a substituted or hydrogenated variant thereof;
• and
• (R1)2N— in formula (II) or A in formula (III) is selected from the group consisting of:
• wherein:
• each dashed line may independently be a bond;
• T is O or S;
• A, B, D, E, W, X, Y and Z, when present, are each independently selected from O, C(R3), C(R3)2, N, N(R3) and S;
• each incidence of R3 is independently selected from the group consisting of hydrogen, halide, cyano, C1-C6 alkyl, C1-C6 trifluoroalkyl, C1-C6 alkoxy, C═O, SO2, acyl, amino, hydroxyl, C5-C6 heteroaryl, C5-C6 heterocyclyl and C3-C6 cycloalkyl, each of which may be optionally substituted;
• and
• n is 0, 1, 2 or 3.

A prodrug of a compound, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is a compound of formula (II) or (III), or a pharmaceutically acceptable salt or solvate thereof:

• wherein:
• each R1 is independently selected from a hydrogen atom and pyrazole, imidazole, triazole, tetrazole, pyrrole, morpholine, piperazine, 4-methyl piperazine, and fused bicyclics or tricyclics comprising a benzene ring fused with at least one 5-membered heterocycle, each of which groups may be optionally substituted at a ring atom with a group selected from halo, isopropyl, morpholinyl, piperidinyl, and piperazinyl, each of which groups may themselves be optionally substituted with C1-C6 alkyl;
• A is selected from pyrazole, imidazole, triazole, tetrazole, pyrrole, morpholine, piperazine, 4-methyl piperazine, and fused bicyclics or tricyclics comprising a benzene ring fused with at least one 5-membered heterocycle, each of which groups may be optionally substituted at a ring atom with a group selected from halo, isopropyl, morpholinyl, piperidinyl, and piperazinyl, each of which groups may themselves be optionally substituted with C1-C6 alkyl;
• and
• W2 and R2 form an indacene group or a substituted or hydrogenated variant thereof.